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ABSTRACT  
 
Zero-time kidney biopsies, obtained at time of transplantation, are performed in many 
transplant centers worldwide. Clinical decisions, decisions on organ allocation and even 
kidney discard are sometimes based on the histological information obtained from these 
biopsies. This comprehensive review evaluates the practical considerations of performing 
zero-time biopsies, the predictive performance of zero-time histology and composite 
histological scores, and the clinical utility of these biopsies. It is concluded that timing of 
these biopsies, at procurement, before implantation or after reperfusion, is crucial. The 
predictive performance of individual histological lesions and of composite scores for post-
transplant outcome is at best moderate. No single histological lesion or composite score is 
sufficiently robust to be included in algorithms for kidney discard. Dual kidney 
transplantation has been based on histological assessment of zero-time biopsies and 
improves outcome in individual patients, but the wait list effects of this strategy remain 
obscure. Zero-time biopsies are valuable for clinical and translational research purposes, 
providing insight in risk factors for post-transplant events, and as baseline for comparison 
with post-transplant histology. The molecular phenotype of zero-time biopsies yields novel 
therapeutic targets for improvement of donor selection, peri-transplant management and 
kidney preservation. It remains however highly unclear whether the molecular expression 
variation in zero-time biopsies could become a better predictor for post-transplant 
outcome than donor/recipient baseline demographic factors. 
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INTRODUCTION 
In 1995, 40 years after the description of the first successful human renal transplants1, 
Gaber and colleagues presented a seminal paper on the association of zero-time biopsy 
histology with outcome after kidney transplantation2. In this publication, the Memphis 
transplantation team described a significant association between zero-time percentage of 
glomerulosclerosis and graft failure, and advocated the use of zero-time biopsies of kidneys 
from older donors and those donors with non-traumatic cerebrovascular accidents. 
Nowadays, zero-time biopsies are performed in many centers worldwide, and clinical 
decisions, decisions on organ allocation and even kidney discard are based on the 
histological information obtained from these biopsies3,4.   
 
A number of studies have re-evaluated the suggestions made by Gaber et al2, and yielded 
many conflicting results and discrepant conclusions, as is clear from a recent systematic 
review5. In addition, donor and recipient characteristics are importantly changing over the 
past decade, with increasing transplantation of kidneys from living donors, from donation 
after cardiac death and from donors with significant clinical risk factors6. This is now 
translated in new allocation rules, like the inclusion of the kidney donor profile index (KDPI) 
formula in the United States6 and the Eurotransplant Senior Program in Europe7. The 
validity of the literature on zero-time biopsy histology in these emerging subpopulations 
has been discussed only scarcely, and its relation with clinical parameters for organ 
allocation remains ill debated. Finally, many research groups have studied novel molecular 
markers in the past decade, but the clinical utility or promise of these markers warrants in-
depth discussion. 
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The present manuscript provides a comprehensive literature review on the value of zero-
time kidney allograft biopsies. 
 
PRACTICAL CONSIDERATIONS 
Zero-time biopsy timing 
The transplantation procedure is a multi-step process, and the timing of performing a zero-
time protocol biopsy could be important, especially given the very different donor types 
(Figure 1). Several studies have evaluated the importance of procurement biopsies (i.e. 
prior to shipment of the kidney), while most studies used kidney biopsies obtained just 
prior to implantation (pre-implantation biopsies). However, for decisions on kidney 
allocation, procurement biopsies are necessary. 
 
Procurement biopsies 
Procurement (“harvest”) biopsies are performed at time of kidney retrieval, prior to the 
period of cold ischemia. The obvious purpose of performing a procurement biopsy, often 
many hours prior to actual implantation (Figure 1), is that renal allograft histology of the 
donor kidney can be used for kidney allocation purposes. This is a prime reason for many 
centers to perform those biopsies. Given the fact that many centers in the United States 
are performing these procurement biopsies in routine clinical practice, several large registry 
analyses have been published, evaluating the relevance of these procurement biopsies. 
Despite wide clinical experience, potential risks associated with performing procurement 
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biopsies have not been evaluated. In European context, procurement biopsies are rarely 
performed.  
 
From histological perspective, it is not expected that there is a difference between the ill-
studied procurement biopsies and pre-implantation biopsies. However, if one would 
consider the use of intrarenal molecular markers (see below), the difference between 
procurement and pre-implantation biopsies becomes highly relevant. Molecular changes in 
procurement biopsies could over-represent the agonal phase and warm ischemia, while 
pre-implantation biopsies also reflect the sometimes-long period of cold ischemia, of 
machine perfusion and other manipulation of the graft in the shipment and preservation 
phase. Data on molecular markers validated and measured in procurement biopsies should 
therefore not be extrapolated automatically to other time points, or vice versa.  
 
Pre-implantation biopsies 
As illustrated in the systematic review by Wang et al, most studies that evaluated the use of 
zero-time biopsies have evaluated histology of biopsies performed immediately prior to 
implantation, during backtable surgery on the kidney. Obviously, the information obtained 
at this time point can not be used for allocation purposes, but only for deciding on last-
minute kidney discard, for prediction of post-transplant outcome and as baseline for 
comparison with post-transplantation biopsies. Pre-implantation biopsies are considered 
histologically similar to procurement biopsies, but molecular changes are also reflective of 
shipment and preservation. Studying the molecular make-up of pre-implantation biopsies 
could therefore be an important tool for research on improving organ preservation. 
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Potential risks associated with performing pre-implantation biopsies have been evaluated 
only by one study, where no serious complications, requiring surgical revision were 
observed8.  
 
Post-reperfusion biopsies 
The literature on post-reperfusion biopsies is very limited. Duman et al have demonstrated 
that performing post-reperfusion biopsies is relatively safe, with 4% of biopsies leading to 
minor bleeding issues without clinical consequence9. In addition to influence of donor 
quality, donor management, organ preservation and shipment conditions, histology and 
molecular phenotype of post-reperfusion biopsies could also reflect ischemia-reperfusion 
injury and allo-immune phenomena.  
 
The impact of ischemia and reperfusion on graft-infiltrating cells was very elegantly 
demonstrated by Koo et al, who showed that deceased donor kidneys often had a 
significant infiltration of recipient-derived neutrophils, while this was not the case after live 
donor kidney transplantation (with very limited ischemia/reperfusion impact)10. Haas et al 
described neutrophil infiltration in post-reperfusion biopsies, although it is important to 
note that neutrophil infiltration was also found in biopsies performed prior to reperfusion. 
This illustrates that not all peri-transplant graft inflammation is recipient-derived11. Also 
brain death in itself has been implicated in the rapid infiltration of macrophages and T cells 
within the first 6 hours after transplantation, at least in animal models12  and in 
procurement biopsies in humans13. Noteworthy, there was significantly more inflammation 
in pre-reperfusion biopsies of brain death donor animals compared to living donor animals, 
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again illustrating that not all inflammation in the peri-transplant period is recipient-
derived12,13.  
 
Next to ischemia-reperfusion injury, post-reperfusion biopsies could also show allo-
immune processes (rejection). Djamali et al described C4d deposition in 93% of cases and 
some glomerulitis (18% of cases) as early as 30 minutes after reperfusion in recipients with 
donor-specific HLA antibodies, even after desensitization14. These data confirmed an 
earlier analysis by Haas et al, who described a few cases of positive C4d staining in post-
reperfusion biopsies of sensitized patients11. Also in ABO blood group incompatible kidney 
transplantation, deposition of C4d, IgG and IgM was noted in 57% of biopsies performed at 
1 hour after reperfusion15. In contrast to these few positive studies, David-Neto et al 
however did neither find deposition of C4d, nor microcirculation inflammation in 1-hour 
post-reperfusion biopsies of sensitized recipients, even in patients with a positive B-cell 
CDC crossmatch16. The reason for these discrepancies is unclear. Taken together, there is 
sufficient evidence that biopsies performed within the first few hours after reperfusion can 
have signs of allo-immune phenomena. However, given the very limited and discrepant 
literature on the value of post-reperfusion biopsies for early evidence of rejection or clinical 
evaluation of ischemia-reperfusion injury, the clinical value of post-reperfusion biopsies 
remains completely unknown.  
 
In addition, a major problem with the interpretation of post-reperfusion biopsies is that 
there is no consensus of timing of this biopsy. As this biopsy is performed at any time point 
during the operation procedure, and as graft inflammation is a very dynamic process, it is of 
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utmost importance to clearly define the exact timing of the post-reperfusion biopsy. 
Differences in timing could lead to very different results, and timing issues could trouble 
correct interpretation of histology and molecular markers in post-reperfusion biopsies.  
 
Wedge vs. core needle biopsy 
As reviewed recently by Wang et al, the majority of centers and studies use wedge biopsies 
for obtaining zero-time kidney transplant histology, while other centers use needle 
biopsies5. This is likely not a trivial issue (Figure 2). As shown by Haas et al, in a direct 
comparison in a small number of living donor kidneys, wedge biopsies underestimate the 
extent of vascular (arterial) intimal thickening, but not the other histological parameters17. 
The findings by Haas et al could be explained by the difference in caliber of the arteries 
sampled in wedge vs. core biopsies. The differences in composition of the other renal 
compartments (glomeruli and tubulo-interstitium) in healthy kidney are potentially less 
pronounced between cortical and subcapsular zones. The fact that this comparison17 was 
made in healthy live kidney donors, inherently with limited chronic renal injury at time of 
transplantation, obviates drawing firm conclusions on these other compartments.  
 
It could very well be that the discrepancies between needle and wedge biopsies become 
more pronounced when more extensive injury is present (e.g. in extended criteria deceased 
donor kidneys), or that these discrepancies also become overt in the glomerular and 
interstitial compartment as differences in vulnerability of the different renal compartments 
are well established. In an earlier study on a limited number of kidneys discarded for 
transplantation, Muruve et al have demonstrated that glomerulosclerosis is significantly 
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more pronounced in the subcapsular zone compared to the cortical zone18. The subcapsular 
zone is situated farthest downstream in the renal artery blood flow, and is therefore most 
at risk for age-related ischemic change. The finding that the number of glomeruli in wedge 
biopsies, to be representative, is higher than assumed19, represents further corroboration 
of the overestimation of the percentage of glomerulosclerosis in wedge biopsies. 19The 
predictive performance of glomerulosclerosis percentage increases significantly with 
increasing number of glomeruli in the wedge biopsy, with best performance when more 
than 24 glomeruli are evaluated19.  
 
To partly overcome the issues with insufficient representation of arterial lesions in wedge 
biopsies, attention should be given to the correct performance of the wedge biopsy, with a 
suggested depth of at least 5 mm20. In addition, sufficiently large samples with a suggested 
minimum number of 15 glomeruli for correct calculation seem necessary, although this last 
number has not been validated19. Recently, the Vienna group has suggested that skin 
punch biopsies could partly overcome these issues, with a significantly lower number of 
inadequate biopsies, without the presumed risks of performing needle biopsies8. Skin 
punch biopsies were 3 mm diameter, which is a larger diameter than core needle biopsies, 
but have a shorter length. The histology of these skin punch biopsies correlated also better 
with post-transplant histology8. Further evaluation of this novel idea is warranted before 
advocating its wider use.   
 
Frozen vs. paraffin-embedded tissue 
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Depending on the clinical application for performing zero-time kidney allograft biopsies, 
e.g. for allocation purposes, it could be necessary to have a fast result, within hours of the 
biopsy. Rapid processing methods to produce paraffin sections with e.g. PAS stains could 
be used, but these methods require an on-call technician and still up to 3 hours until 
histologic sections can be read. Most centers use frozen tissue sections that can be 
prepared and evaluated more rapidly by an on-call pathologist. Frozen sections stained 
with H&E however contain less contrast and changes are subtler than in paraffin-
embedded sections stained with PAS, Masson trichrome and a methenamine silver stain, 
which means that subtle lesions can easily be missed. Furthermore, frozen sections can 
show artifacts that could lead to misinterpretation, like widening of the interstitium21.   
 
Several studies have evaluated the reliability of frozen sections for interpretation of zero-
time renal allograft histology. De Vusser et al correlated the data obtained from frozen 
section with those evaluated in paraffin-embedded tissue sections. In this analysis, based 
on the histological reading by a single, experienced renal transplant pathologist, there was 
a very high concordance between frozen and paraffin-embedded sections, for percentage 
of glomerulosclerosis, interstitial fibrosis/tubular atrophy, vascular (arterial) intimal 
thickening and arteriolar hyalinosis22. Others have also shown that there were no 
statistically significant differences in the extent of glomerulosclerosis, arteriolosclerosis, 
interstitial fibrosis and acute tubular necrosis in frozen sections compared to embedded 
tissue23. It has to be acknowledged however, that sample size in these studies was small 
and histological injury not extensive. The representativeness of these studies for routine 
clinical practice remains therefore questionable.  
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In a much larger study, significant but weaker correlations between frozen and permanent 
sections were observed for vascular (arterial) intimal thickening, glomerulosclerosis 
percentage and interstitial fibrosis (all correlations p<0.001, but r=0.47-0.57)24. Importantly, 
a large proportion of histological lesions would be differently classified in permanent 
compared to frozen sections, which illustrates the inherent difficulty in comparing these 
different methods24. Finally, at the Banff 2013 meeting, it was suggested by the Banff 
working on implantation biopsies, that frozen section wedge biopsies have adequate inter-
observer agreement, better for glomerular than vascular and tubule-interstitial 
parameters25. Further evaluation of these data is awaited.  
 
Pathologist’s experience 
Next to issues with interpretation of frozen sections, centers using zero-time biopsies for 
decisions on kidney graft allocation or discard often rely on histological evaluation by 
different on-call pathologists. Interobserver variability amongst experienced renal 
pathologists is an important issue and may affect the interpretation of the histological 
lesions, and thereby affect the final clinical decisions26. If less experienced on-call 
pathologists have to make a final diagnosis, interobserver variability likely increases. A 
recent study by Azancot et al demonstrated that concordance between on-call pathologists 
and experienced renal pathologists was good for global glomerulosclerosis, but poor for 
vascular (arterial) intimal thickening, interstitial fibrosis, tubular atrophy and arteriolar 
hyalinosis27. Twenty percent of kidneys deemed unacceptable for transplantation by on-call 
pathologists, were considered acceptable according to the experienced renal pathologists. 
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After appropriate training, the concordance with experienced pathologist reading 
improved markedly27. Moreover, in this study, zero-time histology interpreted by on-call 
pathologists did not associate with transplant outcome, while histology reading by 
experienced pathologists did correlated with outcome (renal function at 12 months)27. This 
illustrates that experience is a very important factor in the use of zero-time histology for 
clinical and allocation purposes, and that dedicated training can partly overcome these 
issues with reproducibility and interpretation.  
 
To partly overcome issues of reproducibility and experience, the Banff working group on 
implantation biopsy histology recently suggested that digital slides are equivalent to glass 
slides for evaluation of zero-time kidney graft biopsies25. Further analysis is necessary, but 
this could suggest that it is not necessary to have a trained on-call pathologist at every 
transplant center, but a more centralized and more practical organization could be feasible 
in the future.  
 
From this, as of today, it is questionable whether the practice of dual kidney 
transplantation and of kidney discard (see below), based on donor biopsy evaluation by 
non-experienced pathologists is of any benefit. It is likely that overestimation of lesions in 
zero-time biopsies by lack of experience leads to increased rates of kidney discard and is 
deleterious for the number of effective deceased donor kidney transplants28.  
 
HISTOLOGICAL EVALUATION OF ZERO-TIME BIOPSIES 
Histological grading of individual lesions 
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No specific grading systems for zero-time biopsies have been established. Histological 
interpretation of zero-time renal allograft biopsies has been based on the Banff consensus 
for post-transplant renal allograft pathology, as was also formally advised in the Banff 2007 
update29. In the slowly evolving Banff consensus, chronic histological lesions’ grading 
(tubular atrophy and interstitial fibrosis, arteriolar hyalinosis and vascular/arterial intimal 
thickening) was established in 1993 and updated in 1997, using semiquantitative 
scoring30,31. In addition, the percentage global glomerulosclerosis is calculated in zero-time 
biopsies, similar to what is necessary in post-transplant biopsies31. The validity and 
reproducibility of the Banff scoring system has not been evaluated specifically for zero-time 
biopsies, but it is to be expected that the poor26 to moderate32 reproducibility that is 
observed in post-transplant biopsies also applies at time of transplantation.  
 
Not only chronic histological injury could be of importance in zero-time biopsies. As 
discussed above, inflammation can be present at time of transplantation, and could be of 
interest. Neutrophil infiltration in zero-time biopsies was reported in several older studies, 
both prior to and after reperfusion10,11,13, and there is animal evidence that both innate and 
adaptive immune responses are import. Interstitial inflammation (with any cell type) and 
tubulitis (with mononuclear cells) are routinely evaluated in a standardized way in post-
transplant biopsies according to the Banff classification31. These Banff scores could also be 
used at time of transplantation, but their values and representativeness of the full spectrum 
of zero-time biopsy inflammation remains unstudied in human setting.  
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Histological diagnosis of acute tubular necrosis/injury (cell loss, cell necrosis, regenerative 
changes) is included in the Banff classification25,30,31, has been reported in zero-time 
biopsies11,24,33-36, and semiquantitative scoring has been suggested28,36,37. However, 
histological grading of acute tubular necrosis/injury is not standardized, and it has been 
reported that all preserved kidneys demonstrate acute tubular necrosis to some extent38. 
Given the absence of consensus to grade lesions suggestive of acute tubular necrosis, 
ensuing heterogeneity and very scarce representation in literature, the appropriate grading 
strategy and interpretation of histological signs of acute tubular necrosis in zero-time 
biopsies remains totally obscure.  
 
Finally, other histological lesions have been described in zero-time biopsies, like giant 
mitochondria39 and donor glomerular pathology40-46. As these pre-existing conditions are 
very rare, guidance on the interpretation and implications of these findings only comes 
from individual case reports, and no general conclusions can be made.  
 
Computerized morphometry 
In order to overcome issues with reproducibility and the semiquantitative nature of Banff 
scoring, several groups have evaluated quantitative morphometric evaluation of zero-time 
biopsies. Specific methods for each of the renal compartments have been proposed (Table 
1). Most studied is glomerular volume, where different methods are available and replace 
the gold standard Cavalieri method, which is time-consuming and cumbersome47-49. 
Instead of glomerular volume, glomerular diameter could also be used, as proposed by 
Munivenkatappa et al24. The vascular compartment has been assessed by measuring 
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intima/media ratio, the vessel wall/total area ratio50,51, the arterial wall-to-lumen ratio24 and 
the intimal arterial volume fraction49. Finally, the extent of interstitial fibrosis was 
evaluated by measuring cumulative fibrosis24, the cortical interstitial volume fraction49 or 
the fractional interstitial volume50. Computerized morphometry for interstitial fibrosis 
using Sirius red stains, collagen III stains, or other techniques could potentially provide a 
more reproducible measurement of fibrosis52. A recent Banff working group on fibrosis has 
illustrated that an increasing number of centers have access to these potentially useful 
techniques, with better reproducibility and better correlation with function53. Whether this 
also applies to zero-time biopsies has only been evaluated scarcely. Sund et al used a Sirius 
red method for evaluation of zero-time biopsies54, but the correlation with e.g. donor age 
was unexpectedly less than with visual semiquantitative scoring. 
 
From this, it is clear that different groups have utilized different morphometric approaches, 
none of them being properly validated in larger cohorts. Given the scarcity of information in 
this field, no firm conclusions can be made. The potential advantage of computerized 
imaging needs a lot more work before being implemented in clinical routines. 
 
Composite histological scoring 
Next to scoring individual histological lesions, several studies have evaluated the global 
extent of histological injury in zero-time renal transplant biopsies, using various scoring 
systems. These scoring systems were mostly built by simple addition of the Banff scores for 
individual lesions, most commonly glomerulosclerosis percentage, arteriolar hyalinosis, 
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vascular (arterial) intimal thickening, interstitial fibrosis and tubular atrophy (Table 2)27,49,55-
62.  
 
Only few histologic scoring systems were based on modeling analysis24,49,62. Apart from the 
Maryland Aggregate Pathology Index (MAPI) scoring system, which used graft failure as 
endpoint and which was independently validated in a second cohort24, the other studies 
used DGF62 and eGFR at 3 months49 to build the histological models, and not hard clinical 
end points. In addition, these models were not validated on independent cohorts, which 
may limit their validity.  
 
Most other scoring systems were created without underlying evidence or modeling, but are 
sometimes used more widely: the “Pirani score”58-60, the CADI (Chronic Allograft Damage 
Index)56,57, the “Total Chronic Banff Score”61, and the “Donor Score”27. The composite score 
proposed by Minakawa et al was actually used for early post-transplant biopsies, and is 
therefore not directly applicable to zero-time biopsies63.  
 
All these scores are mathematically calculated by adding individual Banff lesions or variants 
of the Banff scoring system. The MAPI score however makes use of morphometric analysis, 
and includes the wall-to-lumen ratio in interlobular arteries, the extent of periglomerular 
fibrosis and the presence of a scar (focus of sclerosis)24. As these latter lesions are less well 
defined and data on reproducibility are not available, calculating the MAPI score is 
cumbersome in routine clinical practice.  
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Composite clinical-histological scoring 
Because donor demographic and biochemical data could be relevant and provide 
information beyond pure histological evaluation, several groups have proposed integration 
of histological evaluation with clinical parameters for evaluation of zero-time biopsies 
(Table 2). Based on the association with eGFR at 1 year post-transplantation, Anglicheau et 
al have build and validated a donor evaluation system (not exactly a score as only 2 factors 
are taken into account) that integrates a clinical risk factor (high terminal donor serum 
creatinine and/or donor history of hypertension) and glomerulosclerosis percentage64. De 
Vusser et al have modeled the Leuven Donor Risk Score based on the association with long-
term graft failure. This score includes donor age (as continuous parameter), interstitial 
fibrosis/tubular atrophy (IF/TA) grade and glomerulosclerosis percentage, and was 
validated in an independent patient cohort22.  
 
PREVALENCE AND DETERMINANTS OF ZERO-TIME HISTOLOGY 
The prevalence of the different histological lesions observed at zero-time is obviously 
dependent on the donor characteristics. Despite rigorous selection criteria of living kidney 
donors, even live donor kidney zero-time histology is not always pristine, and mild chronic 
histological lesions have been described by several studies, although chronic injury is 
significantly less in living compared to deceased donor kidneys65-69. Both in living and 
deceased donor kidneys, zero-time histology correlates with donor age, cardiovascular risk 
factors and donor renal function22,66,69. Some studies have suggested that replicative 
senescence plays a crucial role in zero-time histological appearance, although further 
validation of this idea is necessary70,71.   
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APPLICATIONS OF ZERO-TIME HISTOLOGY 
Zero-time biopsies are used to assess structural integrity of the donor kidney and to 
provide information on pre-existing donor disease (Figure 3). This evaluation could be 
relevant for decisions on kidney discard, kidney allocation, and choice of peri- and post-
transplant treatment. In addition, Banff consensus on allograft pathology recognized that 
in some cases, the use of a table tracking changes in individual lesions over time, beginning 
with the zero-time biopsy, might be helpful29. However, despite increasing appeal72, Banff 
consensus did not advocate routine use of these biopsies in all patients29.  
 
As a consequence, center practices vary largely, with some centers performing universal 
zero-time histological assessment, other centers not performing zero-time biopsies, and 
the majority of centers performing these biopsies only in specific situations. In an earlier 
study based on SRTR registry data, 74.8% of extended criteria donor kidneys in the United 
States were biopsied prior to transplantation, while this was only the case for 18.7% of 
standard criteria deceased donor kidneys73. The reason for these important discrepancies in 
routine clinical practice between centers lies in the many conflicting data in the literature. 
 
Prediction of post-transplant outcome 
Very recently, Wang et al have summarized the available data in a systematic review on the 
predictive performance of zero-time biopsies for graft outcomes5. For detailed information 
on the specific studies, we refer to this publication. The heterogeneity between the 
different studies in this domain is striking, both in terms of definitions used, in the primary 
endpoint studied, as in technical aspects (wedge vs. needle biopsy, timing of the biopsy, 
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calculated scores vs. individual lesions etc.). Many of these studies were of poor quality.  
Some studies have evaluated graft function as primary outcome measure, while others 
evaluated the association between zero-time histology and delayed graft function (DGF), 
or graft failure5. As outlined below, many centers that reported on the value of zero-time 
biopsies, mainly in the United States, used these biopsies for decisions on kidney allocation 
or discard in their cohorts. This introduces a major bias in the analyses.   
 
Prediction of delayed graft function 
Several studies have evaluated whether zero-time histology associates with DGF. Although 
data are not fully consistent, DGF was not associated with the percentage of 
glomerulosclerosis, histologic scoring systems or interstitial fibrosis/tubular atrophy5. Only 
two smaller studies associated glomerulosclerosis >20% with DGF2,49, but these data were 
not reproduced in subsequent and much larger studies, like the study by Sung et al73. In a 
larger study by Hall et al, histology of acute tubular necrosis in implantation biopsies did 
not associate with DGF in kidneys donated after brain death, and there was only a very 
weak association in kidneys donated after cardiac death74. Arteriolar hyalinosis in zero-time 
biopsies associated with DGF in two studies75,76, while other studies did not investigate this 
explicitly5. Only one small study described a significant association between DGF and 
vascular (arterial) intimal thickening (arteriosclerosis) in zero-time biopsies 49.  
 
Prediction of acute rejection 
In human setting, it has not yet been investigated whether zero-time biopsy 
histology/injury associates with the risk for acute rejection. Several multivariate analyses of 
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clinical risk factors for acute rejection identified increased donor age as a potential variable, 
and also DGF is one of the clearest risk factors for acute rejection77. In addition, subclinical 
rejection on protocol renal allograft biopsies has been associated with increased donor 
age36. The theoretical concept, that pre-existing injury, associated with older donor age, is 
immunogenic and initiates an injury response is supported by scant evidence in animal 
studies that showed upregulation of cytokines and MHC molecules in response to injury78,79.  
 
A micro-array analysis performed at 6 weeks after transplantation showed no difference in 
immune gene expression between deceased and living donor kidneys, the latter having 
considerably less injury80. This could illustrate that the relation between peri-transplant 
injury and allo-immune activation, post-transplant inflammation and acute rejection is not 
very strong in human setting. On the other hand, the combination of advanced donor age 
and pre-transplantation cellular sensitization was shown to increase the risk of acute 
rejection and poor graft function after deceased-donor kidney transplantation, while 
cellular sensitization against younger donor kidneys (with presumably less pre-existing 
injury) did not increase the rejection risk81.  
 
Despite its major importance, the immunogenicity of older or injured donor kidneys has not 
been investigated in human setting, and firm conclusions cannot be made as of today. The 
use of zero-time biopsies for estimation on acute rejection risk, or for decisions on the 
choice of immunosuppression, can therefore not be advocated.  
 
Prediction of graft function 
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The association between zero-time biopsy histology and post-transplant graft function was 
reviewed systematically by Wang et al5. While several studies did not find an association 
between zero-time histology and graft function, the majority of the studies, including the 
largest study in this domain73, described a significant association between zero-time 
histological lesions and impaired graft function5. It remains clouded which histological 
lesion best correlates with eGFR after transplantation. Some studies illustrate that the 
percentage of glomerulosclerosis is a significant correlate with graft function, while others 
have associated eGFR with vascular intimal thickening (arteriosclerosis)5. The presence of 
interstitial fibrosis/tubular atrophy and arteriolar hyalinosis, was not associated with eGFR 
after transplantation, as was reviewed recently5. 
 
Given these associations between individual histological lesions and post-transplant eGFR, 
several combined histological scoring systems associate with eGFR, although this 
association was not evident in all studies5. Ortiz et al have described a clear association 
between delta CADI (0-6 months) and serum creatinine values up to two years after 
transplantation, illustrating that calculating delta scores starting from zero-time histology 
could be a valuable clinical tool to predict renal function57. Further validation and 
calculation of the predictive performance of delta CADI is however necessary. 
 
Prediction of graft failure 
Although eGFR is a valid surrogate endpoint in kidney transplantation, graft failure is the 
most important clinical endpoint. The power to detect associations with graft failure is 
substantially lower than the power to detect differences in eGFR. In several publications, 
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glomerulosclerosis percentage associated with graft failure risk, but this was not consistent 
in all studies5. Two large registry analyses on the UNOS/SRTR databases reported no 
association between the percentage of glomerulosclerosis and graft failure73,82, while 
several single-center studies reported a significant association5. More recently, a trend for 
association between the percentage of glomerulosclerosis and graft failure was observed in 
univariate analysis, but this association was not significant in adjusted multivariate 
analysis83. Similarly, also for vascular injury or tubulo-interstitial damage and graft failure, 
the literature is scattered and no clear consensus is present in the literature on this field5. 
Reflecting these results of individual histological lesions, the association between 
composite histological scores and graft failure was not consistent5.  
 
Decisions on organ allocation and discard 
As illustrated in the preceding chapter, current literature on the association between zero-
time histology and post-transplant outcome is very inconsistent, and no single histological 
marker or composite score is sufficiently robust in predicting graft outcome. Moreover, 
most studies only reported associations, while the predictive performance (accuracy, 
precision, positive predictive value, negative predictive value etc.) of zero-time histology 
for post-transplant events was not studied in detail.  
 
This lack of robust association between zero-time histology and post-transplant outcome is 
of high clinical importance, as many centers are currently performing zero-time biopsies for 
decisions on kidney discard or acceptance, or on kidney allocation. Moreover, it needs to be 
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taken into account that waiting for the results of zero-time histology can lead to delays in 
the transplant procedure, prolonged ischemia time, and ensuing decreased organ quality.  
 
Kidney discard 
Performing procurement biopsies for decisions on kidney discard could lead to an increased 
kidney discard rates. Glomerulosclerosis >20% in procurement biopsies was associated 
with 17-fold increased odds for discard73. In the most recent SRTR yearly report84 and in a 
recent UNOS analysis83, biopsy findings were the most common reason for not 
transplanting a procured kidney:  in 34% of the procured kidneys that were discarded 
(which is 19% of all recovered kidneys), discard was based on the procurement biopsy 
findings. At first sight, based on these data, one could suggest that performing 
procurement biopsies is the cause of high rates of kidney discard in the United States. 
However, these associations do not prove any causality, and caution is warranted. 
Ambiguous kidneys will be biopsied more often, and will more often show "bad" histology, 
whatever this might be. Therefore, it is not clear what is the relative contribution of 
procurement biopsies in high rates of kidney discard, as (financial) risk aversion is also 
inherent to the US allocation system, partly associated with the use of graft and patient 
survival rates as center benchmark for reimbursement 85.  
 
This is not the case in Europe, where only 4.5-10% of kidneys that were accepted by the 
centers for transplantation (which is not completely equal to the kidneys that were 
procured; some kidneys are procured but never accepted) in the Eurotransplant region 
were discarded in the past 10 years, with a trend to increase over the past decade (10.0 % 
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discard in 2014 vs. 4.5% in 2006)86. Kidney discard in Europe is only rarely based on 
procurement or pre-implantation histology data, as procurement biopsies are not 
performed/reported for decisions on organ allocation in the Eurotransplant region, not 
even in extended criteria donor kidneys. In Australia, the rates are substantially lower and 
steady around 3% over the last 10 years, although an increase was noted in the most recent 
evaluation to 6.7%87. The actual impact of biopsy-related kidney discard on overall 
outcome, wait list time and access to transplantation is difficult to study, due to inherent 
bias and geographic differences. 
 
A main problem with the studies that evaluated the association between zero-time 
histology and post-transplant outcome (DGF, eGFR and graft failure) is the fact that in 
some centers, mainly in the United States, zero-time histology is used for decisions on 
kidney discard, which leads to heavy selection bias in the studies that evaluate the 
association between zero-time histology and outcome after transplantation. This can only 
be overcome by specifically evaluating those studies from centers/regions that explicitly 
avoid using zero-time histology for decisions on organ allocation. This is done in a study 
from De Vusser et al, where zero-time biopsies were systematically performed but not used 
for kidney allocation, and the predictive performance of zero-time histology was evaluated. 
This study illustrated that percentage glomerulosclerosis and interstitial fibrosis/tubular 
atrophy associate with graft failure, independent of donor age22.  
 
In addition, this study provided data on the predictive performance of zero-time histology 
(in addition to donor age) for graft failure22. Evaluating predictive performance is 
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important, as a highly significant association does not necessarily translate in clinically 
relevant predictive accuracy. In this study by De Vusser et al, compared to previously 
proposed scoring systems, which were all significantly associated with graft failure in Cox 
proportional hazards analysis (“Total Chronic Banff Score”, “Donor Chronic Damage Score” 
and “Pirani score”; all p≤0.001), the Leuven Donor Risk score was the only score with 
reasonably good predictive accuracy, with a C-statistic of 0.81 (p<0.0001) in the 
independent validation set.  
 
Despite the significant association of the Leuven Donor Risk Score with graft failure, and 
the apparent acceptable predictive accuracy, this score was not sufficient for decisions on 
kidney discard. Many kidneys that would be discarded based on high Leuven Donor Risk 
Scores, would still function at 5 years post-transplantation. In addition, whether the 5-year 
graft survival statistic reflects clinical benefit (improved patient survival, quality of life etc.) 
in comparison with longer waiting time in dialysis if high score kidneys would have been 
discarded, was not evaluated in this study.  
 
Much more data are necessary, and a large-scale multicenter prospective study should be 
set up, to provide insight in which clinical/histological/biochemical parameters are 
necessary or sufficient for decisions on kidney acceptance or discard88. In the meantime, 
clinicians should remain very reluctant to use simple histological prejudices for this 
purpose.  
 
Dual kidney transplantation 
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If, based on clinical or histological criteria, insufficient nephron mass would lead to kidney 
discard of the two procured kidneys, a better option could be to transplant both kidneys 
together in the same recipient (dual kidney transplantation). Already in the first experience 
with dual transplantation of poor-quality kidneys, histological assessment of zero-time 
kidney biopsies was included in the decision algorithms, with the percentage of 
glomerulosclerosis as a decisive parameter89,90. This experience was developed further by 
the Dual Kidney Transplant Group in Italy, which used the “Pirani score”58-60 as a tool to 
allocate kidneys from donors older than 60 years. Kidneys with a score equal or above 4 
were transplanted bilaterally, while kidneys with lower scores were transplanted as single 
grafts. In a long-term follow-up study, it was shown that this approach by using zero-time 
histology for kidney allocation, leads to significantly improved graft survival by 3 years after 
transplantation91. In comparison with discarding both kidneys, successful dual 
transplantation is obviously to be preferred as still one recipient can benefit from these 
poor-quality kidneys.  
 
Another recent Italian study compared outcome of recipients of single vs. dual kidney 
transplantation, as a function of zero-time histological evaluation92. Again, the inclusion of 
zero-time biopsy histology in the allocation algorithm (dual vs. single transplantation) 
makes it impossible to draw firm conclusions regarding the necessity of performing zero-
time histology for allocation decisions. Although outcome was, as expected, significantly 
worse for the cohort of patients who received a single compared to a dual kidney graft, 
>80% of patients who could have received a dual kidney transplant based on histological 
criteria (“Pirani score” = 4) but who were allocated a single kidney, had a functioning kidney 
 28 
up to 3 years post-transplantation. It could thus be questioned whether dual 
transplantation would be wise in these cases. Again, also in this study, the predictive value 
of a “Pirani score” higher than 4 cannot be deduced from this study, as all kidneys with 
these scores were transplanted either as dual transplant or were discarded92.  
 
Although dual kidney transplantation could seem valuable at first sight (graft survival of 
poor-quality kidneys is better after dual kidney transplantation compared to single 
transplantation), this benefit for the individual recipient needs to be weighed against single 
transplantation of both kidneys. In other words, the disadvantage for the potential kidney 
recipient of the second kidney if single transplantation would have been performed, needs 
to be taken into account. This evaluation has not been made yet, as it is cumbersome to 
include wait-listed patients in the analyses, and as retrospective registry data analyses are 
heavily biased. It thus remains highly unclear, which parameters have sufficient accuracy 
for deciding between single and dual transplantation.  
 
In addition, it is unknown how the Italian experiences compare to other allocation 
regimens, like dual kidney transplantation based on the pure clinical Kidney Donor Profile 
Index (KDPI), which seems a valuable alternative83. In this recent study on the OPTN/UNOS 
registry, glomerulosclerosis 15-50% was not independently associated with higher risk of 
allograft failure compared to the reference group with glomerulosclerosis less than 15%. 
Similarly, the Necker group evaluated an algorithm for dual kidney transplantation, not 
taking into account zero-time histology, but donor eGFR93. Grafts from donors with eGFR 
greater than 60 mL/min were allocated to single kidney transplantation, those with eGFR of 
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30–60 mL/min were allocated to dual kidney transplantation, and those with eGFR below 
30 mL/min were discarded. In a substudy, Snanoudj et al demonstrated that scores based 
on histological data from zero-time biopsies did not provide more accurate information 
than donor renal function for allocation of kidneys to single or dual kidney transplantation. 
Although the small size of this population warrants some caution, this study illustrates that 
zero-time histology is not a prerequisite for a valid dual kidney transplant program. 
 
Finally, the real discussion of importance, what are the best parameters for deciding on 
kidney discard, for single or dual kidney transplantation (the “two-one-zero decision”)88 has 
not yet been addressed thoroughly, and the recent UNOS registry study by Tanriover 
illustrates that the absence of clear data leads to important discrepancies between centers 
and organ procurement organizations83. Kidneys that are discarded in one center are being 
used for dual kidney transplantation in another center, or as single graft in two recipients in 
a third center. This study suggests that many kidneys that are currently discarded could be 
better offered for dual transplantation.  
 
Donor-recipient matching for allocation 
As summarized above, the literature on the poor predictive performance of zero-time 
histology illustrates that no algorithm is sufficiently predictive for graft failure to use zero-
time histology in evidence-based decisions on kidney discard or dual kidney 
transplantation. At best, zero-time histology could support decisions on single kidney 
allocation, as part of novel allocation algorithms.  
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However, the practical and logistic issues of implementing zero-time histology in allocation 
procedures, questions on reproducibility and experience (see above), and need for 
independent validation of these findings, obviate its clinical use for allocation purpose. 
Moreover, the direct comparison of combined clinical-pathological scoring systems and 
purely clinical scoring systems, like the “Extended criteria donor” (ECD) criteria94, the 
Kidney Donor Risk Index (KDRI) and the derived Kidney Donor Profile Index (KDPI)95, the 
Nyberg score96, the Pessione score97 etc. has not been made yet. The intrinsic value of 
purely clinical donor risk assessments is beyond the scope of this review, but is already a 
subject of heavy debate98. Further complicating this debate by introducing discussions 
about zero-time histological scores is not supported by sufficient evidence, and currently 
not desirable.  
 
A reasonable conclusion that can be drawn from these studies is that the widespread 
practice of routinely obtaining procurement biopsies (in the United States) for allocation 
purposes or discard should be abandoned, as is currently the case in Europe. In addition, if 
some transplant centers would consider the available data insufficient to draw such a 
strong conclusion, a randomized trial to clearly determine the risks and benefits of using 
procurement biopsies for allocation or discard could be considered28. 
 
Baseline for comparison with post-transplant histology 
As zero-time histology is not suited for prediction of outcome after transplantation, and 
should not be used routinely for decisions on kidney allocation or discard, perhaps the best 
use of zero-time biopsies is as baseline with which future (post-transplant) biopsies can be 
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compared. Pre-existing lesions like vascular (arterial) intimal thickening, percentage of 
glomerulosclerosis, interstitial fibrosis etc. can be recorded, and the same lesions observed 
after transplantation are thus not misconstrued as evidence of post-transplant injury 
processes. Lack of knowledge about the extent of preexisting changes in a zero-time 
kidney complicates the interpretation of post-transplant biopsies20. 
 
Although this reasoning is straightforward and easy to implement in routine clinical 
practice without clear downsides, it is unclear whether the benefit in terms of 
interpretation of post-transplant histology outweighs the additional effort at time of 
transplantation. Very few studies have actually used delta analyses36,99-101, which illustrates 
that even this is not a straightforward application of performing zero-time biopsies. 
Moreover, due to issues of sampling error and because zero-time wedge biopsies are not 
directly similar to post-transplant core biopsies (see above), clinicians need to be careful in 
drawing firm conclusions on histological injury progression over time after transplantation 
in individual cases.  
 
For clinical and translational research purposes however, delta analyses on progression of 
chronic damage, starting at time of transplantation, could become a prerequisite to 
appropriately answer many research questions in studies that include kidneys from non-
standard donors. The most important role of zero-time histology might be in this field, and 
less in daily clinical practice.  
 
Monitoring of (living) donor selection criteria 
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Finally, zero-time biopsy histology could be relevant for evaluation of donor selection 
criteria. Living kidney donors are highly selected based on clinical criteria. There is a trend 
towards expanding the thresholds on acceptable lifetime risk for end-stage renal disease in 
kidney donors102,103. The Mayo Clinic group has suggested evaluating the accuracy of these 
thresholds based on zero-time renal allograft histology, as surrogate “outcome” marker for 
the living donors104. In the Mayo Clinic living donor transplant program, based on the 
specific acceptance criteria, only 4% of zero-time biopsies showed moderate to severe 
histological changes (either arteriolar hyalinosis, interstitial fibrosis, tubular atrophy or 
arterial intimal thickening). Donors of kidneys with chronic injury were older, and had 
higher blood pressure. The low number of kidneys with chronic injury led to the conclusion 
that donor selection criteria are sufficient, and no adaptation were deemed necessary104.  
 
In addition, the authors concluded that it could be helpful to emphasize the importance of 
follow-up for donors determined to have moderate to severe histological lesions at 
donation104. Although this intuitive suggestion sounds very thoughtful, there are no data 
that show an association between living donor zero-time histology and long-term outcome 
after donation. No firm conclusions can thus be made, and advocating zero-time biopsies 
for living donor kidneys is not supported by strong evidence.  
 
Decisions on storage conditions 
Given the revived interest in machine perfusion and techniques for organ reconditioning 
prior to transplantation105, it could be considered to use procurement biopsy histology for 
decisions on storage conditions. As of today, no study has evaluated this topic, but it could 
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be considered to evaluate the potential interaction between storage conditions and zero-
time histology.  
 
MOLECULAR PHENOTYPE OF ZERO-TIME BIOPSIES 
Given the lack of predictive performance of zero-time biopsy histology (see above), many 
research groups have embarked on the search for intrarenal molecular expression as better 
biomarker for post-transplant outcome3,106.  
 
Several studies have evaluated targeted and/or untargeted mRNA, micro-RNA (miRNA) 
and protein expression in zero-time biopsies (obtained during organ retrieval), and 
correlated this with the risk for DGF. In targeted immunohistochemical analysis for 
inflammatory molecules, and targeted RT-PCR mRNA expression analysis of inflammatory 
and stress- or ischemia-related molecules, Nijboer et al demonstrated upregulation of 
these signals in zero-time biopsies from brain-dead compared to living donor kidneys13. 
This is also confirmed by other studies107-109. In addition, in targeted studies, others have 
associated kidney graft function at 1 year with pre-implantation CDKN2A (p16) expression, 
one of the markers of cellular senescence70. 
 
In untargeted microarray gene expression analyses, Hauser et al have described differential 
expression of 48 genes that associate with DGF in pre-implantation biopsies110. Next to 
complement genes that were significantly upregulated in the biopsies of DGF kidneys, also 
many other genes belonging to metabolic, immune and cell communication pathways were 
upregulated in DGF kidneys. Part of this signature was subsequently validated by the same 
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group in micro-dissected zero-time biopsies111. In order to evaluate the association with 
longer-term outcome, Kainz et al have then associated micro-array gene expression data in 
zero-time biopsies with GFR at 1 year after transplantation. In this analysis, donor kidneys 
from recipients with impaired allograft function showed overexpression of genes mainly 
belonging to the functional classes of immunity, signal transduction, and oxidative stress 
response, including several complement genes111.  
 
Similarly, we also described major gene expression differences between living and 
deceased donor kidneys in pediatric kidney recipients112. In this more elaborate data-driven 
pathway analysis in pre-implantation biopsies, again complement genes were significantly 
enriched, and associated with impaired early graft function and also with graft function up 
to 3 years after transplantation112. Next to complement gene expression, many different 
pathways were significantly enriched in deceased donor kidneys, albeit to a lesser extent112. 
A recent and large transcriptomic analysis in the Netherlands confirmed the enrichment of 
hypoxia and complement-and-coagulation pathways in the comparison of deceased versus 
living donor kidneys. Importantly, these expression differences were observed already at 
time of procurement (before cold ischemia) in brain-death donor kidneys, and after first 
warm ischemia in deceased donor kidneys113. This illustrates that these gene expression 
changes are related to death of the donor and warm ischemia, and not primarily the 
consequence of the period of cold ischemia, despite the association of cold ischemia time 
with the level of grade of over-expression of complement genes112.  
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Most studies evaluating gene expression in zero-time biopsies were performed prior to 
reperfusion. In contrast, other studies evaluated the signature of post-reperfusion biopsies, 
by evaluating the expression of selected inflammation-associated markers by RT-PCR. 
They described fair to good predictive performance of the post-reperfusion gene 
expression and DGF, acute rejection and graft function at 6 days to 6 months after 
transplantation114,115. Also the Edmonton group has published about gene expression 
alterations in biopsies obtained after reperfusion, using micro-array gene expression 
analysis. In post-reperfusion biopsies, Mueller et al described less robust gene expression 
differences between kidneys developing DGF versus kidneys with immediate function116. 
The more subtly differentially expressed genes were associated with inflammation and 
immune responses, and to a lesser degree with injury and repair. Interestingly, also after 
reperfusion, this study illustrated a significant overexpression of complement genes in 
deceased versus living donor kidneys, further strengthening the robustness of other studies 
and the persisting overexpression of complement genes in deceased donor kidneys110,112.  
 
In addition, the Edmonton group demonstrated that previously determined gene 
expression signatures of “acute kidney injury”, of “IFN-gamma effects” and of “loss of 
kidney transcrips” correlated significantly with worse graft function at day 7 after 
transplantation, and with DGF117. In multivariate analysis, the “AKI signal” was retained as 
independent associate with DGF (Odds Ratio 5.4), adjusted for donor age. This expression 
signature provided fair predictive performance for DGF with an area under the ROC curve 
(AUC) of 76%, which is better than the predictive performance of donor age, but worse 
than of recipient age in itself (83%). In combination with donor age, predictive performance 
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was improved to an AUC 81%, however still worse than the predictive performance of 
recipient age alone117. As recipient emerged as a more important factor in the prediction of 
DGF and early graft function than the “AKI signal”117, the potential clinical value of this 
post-reperfusion (i.e. when recipient age is known) “AKI signal” remains very unclear. 
Further evaluation of this “AKI signal” in procurement biopsies is warranted to evaluate 
whether the improvement in prediction by adding molecular data to baseline 
demographics, remains present. Only then, this molecular signal could be of clinical value 
for kidney allocation purposes.  
 
Despite the interesting mechanistic insight that is obtained from these studies and the 
potential indication of innovative therapeutic targets (e.g. complement inhibition), the 
formal predictive performance (accuracy, precision, positive and negative predictive value 
etc.) of these markers was not evaluated in these studies, apart from few studies performed 
in post-reperfusion biopsies114,115,117. Moreover, many confounding factors are present in 
these studies (e.g. influence of differences in donor and recipient age, longer cold ischemia 
time, preservation methods etc.), while the studies mentioned above did not correct for 
these different factors, or in case they did, no significant prediction of long-term outcome 
was demonstrated3,117.  
 
It remains thus very unclear whether any of these molecular expression differences in zero-
time biopsies could become a better biomarker/predictor for post-transplant outcome than 
donor/recipient baseline demographic factors. Finally, molecular analysis of zero-time 
biopsies is laborious, time-consuming and dependent on highly variable sample quality, 
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which makes its clinical application, and inclusion in therapeutic decision algorithms in the 
first post-transplant days, highly unlikely.  
 
CONCLUSION 
In conclusion, the above comprehensive literature review illustrates that zero-time biopsies 
are valuable for clinical and translational research purposes, providing insight into risk 
factors for post-transplant problems and in potential novel therapeutic targets. However, 
the clinical utility of performing zero-time biopsies has not been demonstrated. The 
predictive performance of zero-time histology for post-transplant outcome (delayed graft 
function, acute rejection, long-term graft function and graft failure) is poor. Inclusion of 
zero-time histological or molecular information in allocation schemes and in predictive 
models for short- or long-term outcome after kidney transplantation is not supported by 
robust evidence. Kidney discard primarily based on histological interpretation of zero-time 
biopsies should be avoided in routine clinical practice. Finally, it remains highly unclear 
whether the molecular expression variation in zero-time biopsies could become a better 
predictor for post-transplant outcome than donor/recipient baseline demographic factors. 
 
Further research is necessary, in order to evaluate whether and in which indications zero-
time histology could be used for kidney allocation purposes.  The impact on the waiting list 
of histology-guided dual kidney transplantation should be assessed. Large studies should 
evaluate whether zero-time biopsy histology predicts the risk of acute rejection, and could 
help in decisions on immunosuppressive regimen personalization. Finally, the predictive 
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performance for post-transplant outcome, and potential clinical applications, of zero-time 
molecular expression needs further consideration. 
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Key Points 
Timing, technique and pathologist experience have an important impact on the quality of zero-time 
biopsy histological evaluation, and on the molecular phenotype. 
Histological lesions in zero-time biopsies are usually evaluated using the Banff scheme. None of these 
individual lesion Banff scores robustly associates with kidney graft outcome. 
Several composite histological and clinical-histological scoring systems have been proposed. The 
predictive performance of these scores for post-transplant outcome is at best moderate.  
No single histological lesion or composite score is sufficiently robust to be included in algorithms for 
kidney discard.  
Dual kidney transplantation has been based on histological assessment of zero-time biopsies and 
improves outcome in individual patients, but the wait list effects of this strategy remain unclear.  
Histological scoring systems could be used for guiding kidney allocation, although the indication 
remains unclear, practical implementation needs further validation and comparison with pure clinical 
allocation systems is highly cumbersome. The benefit of kidney allocation based on zero-time histology 
has not been demonstrated yet.  
The use of zero-time biopsies for estimation of acute rejection risk, or for decisions on the choice of 
immunosuppression, cannot be advocated due to lack of data.  
It remains highly unclear whether the molecular expression variation in zero-time biopsies could become 
a better predictor for post-transplant outcome than donor/recipient baseline demographic factors. 
Zero-time biopsies are valuable for clinical and translational research purposes, to identify relevant 
therapeutic targets, and for comparison with post-transplant renal allograft histology. 
 
 56 
 
TABLE 1: Evaluation of histological lesions in zero-time biopsies. 
Parameter Definition 
Semiquantitative histological assessment of individual lesions: 
Tubular atrophy Banff “ct” score30,31 
Interstitial fibrosis Banff “ci” score30,31 
Arteriolar hyalinosis Banff “ah”score30,31 
Vascular intimal 
thickening/arteriosclerosis 
Banff “cv” score30,31 
Percentage of glomerulosclerosis  The percentage of the total number of glomeruli affected by global sclerosis 
Acute tubular necrosis Clear definitions are not available 
Inflammation Clear definitions are not available. Banff grading for different histological compartments (“i", “t” etc.) 
could be used 
 
Morphometric analysis of selected histological lesions:  
Glomerular size The average diameter of the four largest glomeruli24 
Mean glomerular volume  Calculated using a point counting method in all glomeruli available in one section, or in a subset of 
glomeruli but in several sections47-49 
Intimal arterial volume fraction Calculated using a point counting method of the intimal area (between inner elastic and lumen), 
divided by the space inside the adventitia49 
Arterial wall-to-lumen ratio  Measure the thickness of opposing two walls (T1 and T2) and the luminal diameter (LD) of the four 
most subjectively affected, well-oriented glomerular arterioles, interlobular arteries and large caliber 
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arteries located in the proximity of the medulla (arcuate/interlobar–size arteries). The wall-to-lumen 
ratio is calculated as (T1 + T2)/LD24 
Intima-media ratio (I/M) of the 
arterial walls  
The ratio of the areas of the intima and of the media of the arterial wall cross-sections, in a sectorial-
elliptic approach50,51 
Vessel wall/total area ratio The ratio of the vessel wall area over the total vessel area50 
Cumulative fibrosis  The percentage of the biopsy surface containing mature collagen by computerized colorimetric 
analysis on Masson’s trichrome stain, including interstitial, glomerular and periarterial fibrosis24 
Cortical interstitial volume fraction Calculated using a point counting method of the interstitial space between tubular membranes49 
Fractional interstitial volume The percentage of interstitium in the total cortical area, after deletion of glomeruli and arterial 
structures, measured on all available cortical sections50 
Cortical fractional interstitial 
fibrosis volume 
The fraction of interstitial fibrosis of the total cortical area, measured by polarized light computerized 
image analysis in sections stained with Sirius red (specific for collagen type I and III)54. 
 
 
 58 
TABLE 2: Calculation and applications of composite histological and clinical-histological scores. 
gs = glomerulosclerosis; ct = Banff tubular atrophy grade; ci = Banff interstitial fibrosis grade; cv = Banff arteriosclerosis grade; i = interstitial 
inflammation grade; mm = mesangial matrix increase grade; cg = transplant glomerulopathy grade; if/ta = Banff interstitial fibrosis/tubular 
atrophy grade30,31. 
 Reference Calculation Range Development Clinical application 
Composite histological scores 
 “Pirani Score” Pirani et al; 
Remuzzi et al; 
Karpinski et al58-60 
gs + ct + ci + cv   (gs 0% = 0; 
<20% = 1; 20-50% = 2; >50% 
= 3; ct, ci and cv scores are 
not in full concordance with 
Banff grading) 
0 - 12 Clinical 
judgment 
Associates with graft failure, but poor predictive 
performance22,91. Used in some centers for decisions on dual 
kidney transplantation, despite unclear wait list effects. 
“Donor 
Score” 
Azancot et al27 gs + ct + ci + cv + ah (gs 0% = 
0; 1-10% = 1; 11-20%=2; 
>20% = 3) 
0 - 15 Clinical 
judgment 
Associates with graft function up to one year post-
transplantation, and with a composite of graft failure and 
graft functional decline27. The predictive performance is 
unclear.  
“Chronic 
Allograft 
Damage 
Index” (CADI)  
Ortiz et al57 gs + ct + ci + cv + mm + i (gs 
0% = 0; 1-15% = 1; 16-50% = 
2; >50% = 3) 
0 - 18 Clinical 
judgment 
Associates with post-transplant CADI and could be used as 
baseline for post-transplant comparison as delta-CADI 
correlates with graft function up to 2 years after 
transplantation. Association with graft failure was not 
evaluated57. 
“Chronicity 
Index” 
Sund et al55 gs + if/ta + cv + ah + i (gs 
score = combination of global 
glomerulosclerosis and 
grades of sclerosis in 
0 - 15 Clinical 
judgment 
Not established. 
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preserved glomeruli) 
“Total 
Chronic Banff 
Score” 
Snoeijs et al61 cg + mm + ct + ci + cv + ah + 
gsfraction x 3 (gsfraction = 0 
to 1) 
0 - 21 Clinical 
judgment 
Associates with graft failure, but the predictive performance 
is poor22,61.  
“CIV Score” Balaz et al62 ci + cv 0 - 6 Modeling Associates with delayed graft function, but the predictive 
performance is poor62. 
“Donor 
Chronic 
Damage 
Score” 
Lopes et al49 ci + cv + gs  (gs ≤ 10% = 0 ; > 
10% = 1) 
0 - 7 Modeling Associates with graft function and graft failure22,49, but the 
predictive performance is poor22. 
“MAPI Score” Munivenkatappa et 
al24 
ah (absent = 0; present = 4) + 
periglomerular fibrosis 
(absent = 0; present = 4)  +  
arterial wall-to-lumen ratio 
(<0.5 = 0; ≥ 0.5 = 2) + scar 
(absent = 0; present = 3) + gs 
(<15% = 0;  ≥ 15% = 2)  
0 - 15 Modeling + 
independent 
validation 
Associates with graft failure, but the predictive performance 
is moderate at best24. 
Clinical-histological scores 
“Paris 
Composite 
Score“ 
(for donors ≥ 
50 years) 
Anglicheau et al64 donor creatinine (<150 
μmol/L =0; ≥150 μmol/L) 
and/or donor hypertension 
(absent 0; present = 1) + gs 
(gs <10% = 0; ≥10% = 1) 
0 - 2 Modeling + 
independent 
validation 
Associates with eGFR at 1 year post-transplant, and with 
graft failure. The predictive performance is good for eGFR at 
1 year, but poor for graft failure64.  
“Leuven 
Donor Risk 
Score” 
De Vusser et al22 donor age (years) + gs + 3 x 
if/ta  
(gs <10% = 0; ≥10% = 1) 
1 - … Modeling + 
independent 
validation 
Associates with graft failure. The predictive performance for 
graft failure is moderate22. 
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Figure Legend 
 
Figure 1. Timing of performing a kidney graft zero-time biopsy, according to donor 
type.  
Procurement biopsies are performed in deceased donor kidney transplants at time of 
retrieval of the donor kidney. Histology and molecular alterations in procurement biopsies 
reflect baseline donor characteristics and the effects of the agonal phase, brain death and 
first warm ischemia time. Pre-implantation biopsies are performed just prior to the 
implantation of the kidney, before anastomosis time. Histological and molecular changes 
reflect the donor characteristics, the agonal phase, but also the period of cold ischemia 
during organ storage and shipment. Finally, post-reperfusion biopsies are performed after 
opening the clamps at the end of the anastomosis time. These biopsies reflect baseline 
donor characteristics, the agonal phase, periods of warm and cold ischemia. In addition, 
and most importantly, post-reperfusion biopsies reflect reperfusion of the transplanted 
kidney, and thus also ischemia-reperfusion injury, and potentially allo-immune phenomena 
(allograft rejection). In living donor kidneys, cold ischemia time is usually minimal, unless 
kidneys are shipped to another hospital after extraction (e.g. in living donor exchange 
programs).   
 
ET = extraction time; CIT = cold ischemia time; WIT = warm ischemia time; AT = 
anastomosis time; DBD = donation after brain death; DCD = donation after cardiac death 
(Maastricht category II or III); = time of death of the donor. 
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Figure 2. Techniques for obtaining zero-time biopsies vary importantly.  
The choice of technique impacts on the diagnostic value of different histological lesions.  
 
Figure 3. Applications of performing zero-time biopsies, and factors impacting their 
histology and molecular phenotype.  
*Reperfusion injury and allo-immune phenomena only impact on histology and molecular 
expression in post-reperfusion biopsies.
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